AllianceBernstein’s Terns Pharmaceuticals TERN Stock Holding History

AllianceBernstein’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,032,679	Closed	-$41.7M	–	3430
2026 Q1	$41.7M	Sell	1,032,679 -255,400	-20%	-$10.5M	0.01%	656
2025 Q4	$52M	Buy	1,288,079 +1,195,179	+1,287%	+$27.6M	0.02%	614
2025 Q3	$698K	Hold	92,900	–	–	﹤0.01%	2512
2025 Q2	$347K	Buy	92,900 +28,800	+45%	+$89.9K	﹤0.01%	2844
2025 Q1	$177K	Sell	64,100 -298,259	-82%	-$1.22M	﹤0.01%	2955
2024 Q4	$2.01M	Buy	362,359 +117,783	+48%	+$798K	﹤0.01%	1956
2024 Q3	$2.04M	Sell	244,576 -53,488	-18%	-$440K	﹤0.01%	1958
2024 Q2	$2.03M	Buy	298,064 +278,854	+1,452%	+$1.69M	﹤0.01%	1945
2024 Q1	$126K	Sell	19,210 -6,740	-26%	-$44K	﹤0.01%	3002
2023 Q4	$168K	Hold	25,950	–	–	﹤0.01%	3008
2023 Q3	$131K	Buy	25,950 +5,230	+25%	+$33.2K	﹤0.01%	3030
2023 Q2	$181K	Buy	+20,720	New	+$241K	﹤0.01%	3004

Other funds holding TERN

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

AllianceBernstein's TERN Position: Q2 2026 in Review

AllianceBernstein sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 1,032,679 shares — an estimated $41.7M sold.

AllianceBernstein first reported a position in TERN in Q2 2023 and held it in 12 quarters. The position peaked at $52M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

AllianceBernstein reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
AllianceBernstein sold 1,032,679 Terns Pharmaceuticals shares in Q2 2026, an estimated $41.7M.
AllianceBernstein first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 12 quarters.
AllianceBernstein's Terns Pharmaceuticals position peaked at $52M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.